Abstract | BACKGROUND: METHODS: RESULTS: Patients with ACS showed significantly enhanced GPVI expression levels compared to patients with SAP or NC causes of chest pain (ACSvs.SAP(mean fluorescence intensity (MFI)+/-SD):18.9+/-7.4vs.17.9+/-9.5;P=0.028;ACSvs.NC:15.4+/-6.9;P=0.002). Elevated GPVI expression was associated with ACS independent of markers of myocardial necrosis like troponin and creatine kinase-MB. Patients with an elevated GPVI expression (MFI>or=18.6) had a poorer clinical outcome than patients with baseline GPVI expression in regard to composite cumulative survival that included myocardial infarction, stroke, and cardiovascular death at three months (Log rank;P=0.025). DISCUSSION: Platelet GPVI surface expression is enhanced in patients at risk for an ACS and is an early marker for imminent acute coronary events in patients with chest pain.
|
Authors | Boris Bigalke, Michael Haap, Konstantinos Stellos, Tobias Geisler, Peter Seizer, Elisabeth Kremmer, Dietrich Overkamp, Meinrad Gawaz |
Journal | Thrombosis research
(Thromb Res)
Vol. 125
Issue 5
Pg. e184-9
(May 2010)
ISSN: 1879-2472 [Electronic] United States |
PMID | 20122713
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright (c) 2010 Elsevier Ltd. All rights reserved. |
Chemical References |
- Biomarkers
- Platelet Membrane Glycoproteins
- platelet membrane glycoprotein VI
|
Topics |
- Acute Coronary Syndrome
(blood, diagnosis)
- Aged
- Biomarkers
(blood)
- Chest Pain
(blood, diagnosis)
- Female
- Humans
- Male
- Middle Aged
- Platelet Membrane Glycoproteins
(analysis)
- Reproducibility of Results
- Sensitivity and Specificity
|